Zusammenfassung
Progesteron ist essenziell für die Bereitstellung eines rezeptiven Endometriums und für die Aufrechterhaltung einer Frühschwangerschaft. Während Progesteron bei einer Konzeption im Spontanzyklus vom Corpus luteum produziert wird, ist die Lutealphase nach hormoneller Stimulation zur Vorbereitung auf die In-vitro-Fertilisation oder intrazytoplasmatische Spermieninjektion von einer unterschiedlich stark ausgeprägten Lutealphaseninsuffizienz gekennzeichnet. Die Notwendigkeit einer Lutealphasensubstitution ist unumstritten und die Wahl derselben muss an die vorausgegangene Therapie angepasst werden. „Minimale“ und „optimale“ Progesteronwerte zum Erreichen und Erhalt einer Schwangerschaft sind weder für Transferzyklen mit frischen Embryonen noch für Transferzyklen mit kryokonservierten Embryonen eindeutig definiert.
Abstract
Progesterone is essential for endometrial receptivity, implantation and the maintenance of an early pregnancy. In spontaneous conception cycles, progesterone is produced by the corpus luteum; however, after hormonal stimulation for preparation for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) the luteal phase is characterized by a variably severe luteal phase insufficiency. The necessity for a luteal phase support is indisputable and has to be selected according to the preceding treatment. So far, “minimal” and “optimal” ranges of progesterone levels to achieve and maintain a pregnancy are not clearly defined, neither for transfer cycles with fresh embryos nor for transfer cycles with frozen embryos.
This is a preview of subscription content, access via your institution.
Literatur
Alsbjerg B, Thomsen L, Elbaek HO, Laursen R, Povlsen BB, Haahr T, Humaidan P (2018) Progesterone levels on pregnancy test day after hormone replacement therapy-cryopreserved embryo transfer cycles and related reproductive outcomes. Reprod Biomed Online 37(5):641–647
Beckers NG, Macklon NS, Eijkemans MJ et al (2003) Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 88:4186–4192
Christenson LK, Devoto L (2003) Cholesterol transport and steroidogenesis by the corpus luteum. Reprod Biol Endocrinol 10:90
Cometti B (2015) Pharmaceutical and clinical development of a novel progesterone formulation. Acta Obstet Gynecol Scand 94:28–37
Csapo AI, Pulkkinen MO, Wiest WG (1973) Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 115:759–765
Daily CA, Laurent SL, Nunley WC (1994) The prognostic value of serum progesterone and quantitative J3-human chorionic gonadotropin in early human pregnancy. Am J Obstet Gynecol 171(2):380–383
Damewood MD, Shen W, Zacur HA et al (1989) Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 52:398–400
Devoto L, Fuentes A, Kohen P et al (2009) The human corpus luteum: life cycle and function in natural cycles. Fertil Steril 92:1067–1079
Devroey P, Palermo G, Bourgain C et al (1989) Progesterone administration in patients with absent ovaries. Int J Fertil 34:188–193
Dosouto C, Haahr T, Humaidan P (2017) Gonadotropin-releasing hormone agonist (GnRHa) trigger—state of the art. Reprod Biol 17(1):1–8. https://doi.org/10.1016/j.repbio.2017.01.004
Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13(6):581–590
Fatemi HM (2009) The luteal phase after 3 decades of IVF: What do we know? Reprod Biomed Online 19:4331
Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B et al (2013) Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone—gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 100:742–747
Fauser BC, Devroey P (2003) Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14:236–242
Filicori M, Santoro N, Merriam GR, Crowley WF Jr (1986) Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 62(6):1136–1144
Fishel SB, Edwards RG, Evans CJ (1984) Human chorionic gonadotropin secreted by preimplantation embryos cultured in vitro. Science 11:816–818
Gaggiotti-Marre S, Álvarez M, González-Foruria I, Parriego M, Garcia S, Martínez F, Barri PN, Polyzos NP, Coroleu B (2020) Low progesterone levels on the day before natural cycle frozen embryo transfer are negatively associated with live birth rates. Hum Reprod 35(7):1623–1629
Hull MG, Savage PE, Bromham DR, Ismail AA, Morris AF (1982) The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (“ovulation”) derived form treated and untreated conception cycles. Fertil Steril 37(3):355–360
Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20(5):1213–1220
Jordan J, Craig K, Clifton DK, Soules MR (1994) Luteal phase deficiency: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil Steril 62:54–62
Kofinas JD, Blakemore J, McCulloh DH, Grifo J (2015) Serum progesterone levels greater than 20 ng/dl on day of embryo transfer are associated with lower live birth and higher pregnancy loss rates. J Assist Reprod Genet 32(9):1395–1399
Kol S, Breyzman T (2016) GnRH agonist trigger does not always cause luteolysis: a case report. Reprod Biomed Online 32(1):132–134
Kol S, Breyzman T, Segal L, Humaidan P (2015) ‘Luteal coasting’ after GnRH agonist trigger—individualized, HCG-based, progesterone-free luteal support in ‘high responders’: a case series. Reprod Biomed Online 31(6):747–751
Kolibianakis EM, Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5:26–35
Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, Bosch E (2017) Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod 32(12):2437–2442
Lawrenz B, Sibal J, Garrido N, Abu E, Jean A, Melado L, Fatemi HM (2018) Inter-assay variation and reproducibility of progesterone measurements during ovarian stimulation for IVF. PLoS ONE 13(11):e206098
Lawrenz B, Garrido N, Samir S, Ruiz F, Melado L, Fatemi HM (2017) Individual luteolysis pattern after GnRH-agonist trigger for final oocyte maturation. PLoS ONE 12(5):e176600
Lawrenz B, Samir S, Melado L, Ruiz F, Fatemi HM (2018) Luteal phase serum progesterone levels after GnRH-agonist trigger—How low is still high enough for an ongoing pregnancy? Gynecol Endocrinol 34(3):195–198
Lawrenz B, Samir S, Garrido N, Melado L, Engelmann N, Fatemi HM (2018) Luteal coasting and individualization of human chorionic gonadotropin dose after gonadotropin-releasing hormone agonist triggering for final oocyte maturation—a retrospective proof-of-concept study. Front Endocrinol (Lausanne) 9:33. https://doi.org/10.3389/fendo.2018.00033
Loke YW, King A, Burrows TD (1995) Decidua in human implantation. Hum Reprod 10(Suppl 2):14–21
Macklon NS, Fauser BC (2000) Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil 55:101–108
Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 62:485–490
Nakajima ST, Nason FG, Badger GJ, Gibson M (1991) Progesterone production in early pregnancy. Fertil Steril 55(3):516–521
Neumann K, Depenbusch M, Schultze-Mosgau A, Griesinger G (2020) Characterization of early pregnancy placental progesterone production by use of dydrogesterone in programmed frozen-thawed embryo transfer cycles. Reprod Biomed Online 40(5):743–751
Nillius SJ, Johansson ED (1971) Plasma levels of progesterone after vaginal, rectal, or intramuscular administration of progesterone. Am J Obstet Gynecol 110:470–477
Patton PE, Lim JY, Hickok LR, Kettel LM, Larson JM, Pau KY (2014) Precision of progesterone measurements with the use of automated immunoassay analyzers and the impact on clinical decisions for in vitro fertilization. Fertil Steril 101(6):1629–1636
Practice Committee of the American Society for Reproductive Medicine (2012) The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril 98(5):1112–1117
Psychoyos A (1973) Hormonal control of ovoimplantation. Vitam Horm 31:201–256
Simon C, Martın JC, Pellicer A (2000) Paracrine regulators of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 14:815–826
Stricker R, Eberhart R, Chevailler M‑C, Quinn FA, Bischof P, Stricker R (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44:883–887
Thomsen LH, Kesmodel US, Erb K, Bungum L, Pedersen D, Hauge B, Elbæk HO, Povlsen BB, Andersen CY, Humaidan P (2018) The impact of luteal serum progesterone levels on live birth rates—a prospective study of 602 IVF/ICSI cycles. Hum Reprod 33(8):1506–1516
Vuong LN, Ho TM, Pham TD, Ho VNA, Andersen CY, Humaidan P (2020) The early luteal hormonal profile in IVF patients triggered with hCG. Hum Reprod 35(1):157–166
Yovich JL, Conceicao JL, Stanger JD, Hinchliffe PM, Keane KN (2015) Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement. Reprod Biomed Online 31:180–191
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
B. Lawrenz und H.M. Fatemi geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
G. Griesinger, Lübeck
Rights and permissions
About this article
Cite this article
Lawrenz, B., Fatemi, H.M. Gibt es optimale Serumprogesteronwerte in In-vitro-Fertilisations- und Kryozyklen?. Gynäkologische Endokrinologie 19, 118–123 (2021). https://doi.org/10.1007/s10304-020-00366-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10304-020-00366-3
Schlüsselwörter
- Hormonelle Stimulation
- IVF/ICSI
- Lutealphase
- Transfer frischer Embryonen
- Verfahren der assistierten Reproduktion/Outcome
Keywords
- Hormonal stimulation
- IVF/ICSI
- Luteal phase
- Embryo transfer, fresh
- Reproductive techniques, assisted/outcome